On December 2021, US FDA permitted an Emergency Use Authorization for the treatment of mild to moderate COVID-19 in people who are at high-risk for progression to severe COVID-19 to Pfizer for Paxlovid, a combination of two inhibitors: ritonavir and Nirmatrelvir (PF-07321332).
The model above shows the biomolecular interactions between the SARS-CoV-2 Main protease and its inhibitor (PF-07321332). In this diagram the inhibitor (PF-07321332) is shown with green Carbons, blue Nitrogen, red Oxygens, and Florine as deepcyane. While the main protease is colored where the carbon is “salmon”, blue Nitrogen, and red Oxygens and the rest of the protease is colored grey. The dashed lines shows where bonds occur between the inhibitor and the protease, these bonds include Hydrogen bonds, covalent bonds, and hydrophobic interactions.
Comments